Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439898 | 0.93 | PTGER1 (0.54) | PTGER1CYP2C9CNR1 | |
| SCHEMBL4154357 | 0.92 | PTGER1 (0.46) | PTGER1CYP2C9CNR1MEN1HSP90AA1 | |
| SCHEMBL4146593 | 0.91 | PTGER1 (0.46) | PTGER1CYP2C9CNR1MAPT | |
| SCHEMBL4150169 | 0.91 | PTGER1 (0.44) | PTGER1CYP2C9CNR1MEN1KMT2A | |
| SCHEMBL4154000 | 0.91 | PTGER1 (0.42) | PTGER1CYP2C9MAPT | |
| SCHEMBL4155622 | 0.89 | PTGER1 (0.52) | PTGER1CYP2C9CNR1 | |
| SCHEMBL4149183 | 0.89 | PTGER1 (0.49) | PTGER1CYP2C9MEN1HSP90AA1KMT2A | |
| SCHEMBL4149960 | 0.88 | PTGER1 (0.42) | PTGER1CYP2C9MEN1KMT2A | |
| SCHEMBL4149186 | 0.88 | PTGER1 (0.41) | PTGER1CYP2C9MEN1KMT2A | |
| SCHEMBL4168715 | 0.88 | PTGER1 (0.41) | PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885CNR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.